Endometrial Polyps Regression With Progesterone Therapy

• Status: Unknown status
• Trial end date: 2019-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

This prospective randomized study will compare the regression rates of women managed with watch-and-wait approach and of those treated with 3 cycles of luteal 25mg subcutaneous progesterone from 18 to 25 days of menstrual cycle

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Magna Graecia
• Treatments: Progesterone

Criteria

Inclusion Criteria:

• ultrasound diagnosis of endometrial polyps no more than 30 days before the enrollment

• signed informed consent

Exclusion Criteria:

• estrogenic and\or progestinic therapy two months before the enrollment

• tamoxifen therapy

• pelvic inflammatory disease

• gynaecologic neoplasia

• previous chemotherapy and radiotherapy

• autoimmune diseases, chronic disease, metabolic, and endocrine (hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease)

• menopause

• Hypogonadotropic hypogonadism

• drugs causing menstrual irregularities